不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>2009年罗氏基因组富集的序列捕获技术服务通过SeqWright推出

2009年罗氏基因组富集的序列捕获技术服务通过SeqWright推出

Roche2011年2月28日 9:40 点击:1904

美国Roche NimbleGen  美国Roche 454 Life Sciences


 瑞士罗氏Roche 美国SeqWright  


 

Roche宣布用于基因组富集的序列捕获技术服务已通过服务合作商SeqWright推出
 
Roche NimbleGen宣布,通过与世界领先的常规基因组和分子生物学服务商SeqWright合作,目前可推出序列捕获技术服务。SeqWright可提供目标再测序服务,其中结合了Roche NimbleGen的序列捕获微阵列技术与SeqWright的454 Genome Sequencer FLX测序服务。NimbleGen目标序列捕获芯片技术与SeqWright业务的合并有助于公司推出最先进和最具全面的目标再测序服务。SeqWright的客户可利用
NimbleGen 2.1M人外显子芯片或常规的目标人类再测序服务,对100kb至30Mb的外显子进行测序。这项服务可显著缩短目标和人类外显子再测序所需的时间,并降低成本,从而使这类研究在研究者中更为普及。

SeqWright的CEO,Dr.Fei Lu称:“我们很高兴能提供快速、高性价比的服务,能使研究人员在基础和临床研究中增加对于遗传疾病因子的认识。NimbleGen序列捕获微阵列与下一代测序是技术之间完美的结合。作为CLIA认证的实验室,提供这项服务有助于目标再测序和外显子组测序在疾病通路、癌症以及更多研究中的应用。”

Roche NimbleGen的CEO,Dr.Gerd Maass认为,“目标富集和测序是热点研究取得的重大进展,能够加深我们对于遗传修饰差异的理解。它对于个体化医疗保健具有非常深远的影响,目前,我们可以在单一微阵列上快速靶定和破译最具相关性的基因组,-人类外显子。这项技术提供了更快速和更具性价比的方法,帮助我们理解常见和复杂疾病,从而促进诊断和治疗。与SeqWright的合作有助于推进遗传探索和研究,并更广泛地利用这些前沿技术。”

技术背景
人类外显子测序是再测序研究中的“圣杯”,它最终会促进生物医学领域的重大突破。外显子是基因组中与功能最具相关性的片段,由DNA短片段组成,可提供蛋白的遗传蓝图。因此,外显子测序可发现导致许多常见病和罕见病(例如癌症和阿尔茨海默病)的功能变异。通过外显子再测序也可阐明为何某些疾病,如糖尿病在特定人群中较为常见,并且有助于解释为何药物仅仅在某些个体或亚人群中有效。在NimbleGen序列捕获2.1M人外显子微阵列问世前,外显子测序在技术或经济学上均不具有不可行性,原因是常规的PCR技术在制备“全套”人类编码外显子上过于昂贵和费时。2009年,来自Roche NimbleGen的最新技术,序列捕获2.1M人外显子和454 Life Sciences,GS FLX Titanium Sequencing System使完成人类外显子测序成为现实,并最终使这些技术走上研究流水线,并促进个体化医疗保健的发展。Roche NimbleGen是具有专利的DNA微阵列、耗材、仪器和服务的领先创造者、生产商和供应商。Roche NimbleGen生产长寡核苷酸探针的高密度微阵列,为基因组和表观基因组变异的研究提供了更多的信息和更高质量的数据。这种性能的提高是通过Roche NimbleGen专利的无膜芯片合成(MAS)技术,该技术使用了数字光处理和快速、高产的光化学技术,以极高的灵活性合成长寡核苷酸、高密度的DNA微阵列。
 
关于罗氏
罗氏始创于1896年,总部位于瑞士巴塞尔,在制药和诊断领域是世界领先的以研发为基础的健康事业公司之一。作为世界上最大的生物科技公司,罗氏提供从早期发现、预防、诊断到治疗的创新产品与服务,在诸多领域都做出了突出的贡献,从而提高了人类的健康水准和生活质量。罗氏是体外诊断领域、抗肿瘤药品和移植药品的全球领先者,是病毒学领域的市场领导者。在其它关键疾病领域如自身免疫性疾病、炎症、代谢和中枢神经系统疾病等同样表现活跃。2008年,药品部的销售额达360亿瑞士法郎,诊断部的销售额达97亿瑞士法郎。2008年,罗氏在研发方面的投入超过了90亿瑞士法郎,并与多个合作伙伴建立了研究与开发的业务联盟,包括罗氏控股的基因泰克和中外制药。罗氏集团共拥有约8万名员工。

Branford, CT, USA, July 30, 2009

454 Life Sciences and Roche NimbleGen Announce Collaboration with Eli Lilly and SeqWright to Sequence Genomic Regions Associated with Psychiatric Disease

454 Life Sciences, a Roche company, and Roche NimbleGen, both units of Roche Applied Science, have announced a collaboration with Eli Lilly and Company and SeqWright, a world-wide leader in custom genomic and molecular biology services. The goal of this collaboration is to use leading edge genomic technologies to identify genetic variants possibly associated with various psychiatric diseases. SeqWright will utilize NimbleGen Sequence Capture technology to selectively enrich approximately 40 megabases of the human genome, which will then be comprehensively sequenced using 454 Life Sciences’ Genome Sequencer FLX System.

By utilizing the most advanced genomic technologies, SeqWright has the ability to transform the drug discovery process by reducing the time and money necessary for researchers to identify potentially clinically informative genetic variations.

不用本金就能赚钱的方法“Just a year ago, it would have been impossible to imagine how we could selectively sequence such a large portion of the human genome in such a fast and cost effective manner. Our goal at Lilly is to improve the outcomes of individual patients; increasing the speed at which we begin to understand the basis of disease is critical to improving those outcomes,” stated Brian Edmonds, Ph.D., Research Advisor, Global External Research and Development, Eli Lilly and Company. “We are participating in this collaboration as a way to better examine the root causes of various psychiatric diseases. If this project delivers as expected, we hope to identify new biomarkers or novel drug targets for future development of medicines to treat an array of psychiatric illnesses.”

不用本金就能赚钱的方法“SeqWright continues to invest in cutting edge technologies to help change how researchers can advance their understanding of human genetics. We have previously used the combination of NimbleGen capture arrays with the 454 Sequencing System in other areas with great success. The possibility to advance the scope of these technologies, from basic research applications to use in clinical research applications in the future, is showing enormous potential ,” stated Fei Lu, M.D., CEO of SeqWright. “As a CLIA certified facility, where we employ and evaluate these new research technologies, we are ready to help move the industry closer to the goal of personalized medicine in the future, where identifying genetic variations within the human genome in a fast and accurate method will be of paramount importance.”

Technology Background

Roche NimbleGen is a leading innovator, manufacturer, and supplier of a proprietary suite of DNA microarrays, consumables, instruments, and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen’s proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing, and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company’s website at 不用本金就能赚钱的方法www.nimblegen.com

不用本金就能赚钱的方法454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative 454 Sequencing system for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of the 454 Sequencing system are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired-end reads. The technology of the 454 Sequencing system has enabled hundreds of peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology and many more.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.  As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.  It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system.  In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs.  Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007.  Worldwide, the Group employs about 80,000 people. Additional information is available at 不用本金就能赚钱的方法www.roche.com

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world’s most urgent medical needs. Additional information about Lilly is available at 不用本金就能赚钱的方法www.lilly.com.

About SeqWright

Based in Houston, TX, SeqWright Incorporated is recognized as an international leader in the field of contract genomic services which now include multiple next generation sequencing platforms. With more than fifteen years of experience, SeqWright specializes in state-of-the-art Molecular Biology and Genomic services, from small projects up to full clinical trials, within a highly regulated GLP/CLIA environment. SeqWright was recently awarded a license by the state of California to operate as a clinical laboratory. This license, along with CLIA certification, allows SeqWright to handle clinical samples from vast majority of  the United States. For additional information about SeqWright and its services, please visit 不用本金就能赚钱的方法www.seqwright.com.

All products are sold for life science research use only. Not for use in diagnostic procedures.
不用本金就能赚钱的方法 454, 454 SEQUENCING, 454 LIFE SCIENCES, GS FLX TITANIUM, and NIMBLEGEN are trademarks of Roche.

 


 

(来源: Roche )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图